13F Insight
DOSSIER · 13F-HR · Q1 2026

Clayton, Dubilier & Rice, LLC

$536M in tracked AUM across 2 positions as of Q1 2026.

CD
CIK 0001538642 · last filed Mar 31, 2026
Total AUM
$536M
as of Q1 2026
Holdings
2
—
positions
Whale Score
73
73
strong
Activity
—
no data
changes this Q
AI Analysis · Q1 2026
Comprehensive Analysis of Clayton, Dubilier & Rice, LLC 13F Filing
1. Portfolio Overview

Clayton, Dubilier & Rice (CD&R) presents a highly concentrated and non-diversified portfolio as of the reporting period September 30, 2025. The total portfolio value surged significantly to $676.71 million, marking an increase of 89.4% from the $357.29 million reported in the previous quarter. This rapid expansion in asset value is driven almost entirely by aggressive accumulation rather than broad mar...

2. Key Holdings

The portfolio is dominated by two distinct positions, with Resideo Technologies, Inc. (REZI) serving as the anchor holding.

  • Resideo Technologies, Inc. (REZI): This is the overwhelming core position, valued at $573.71 million and representing 84.78% of the total portfolio. CD&R holds 13.29 million shares, a substantial stake that likely gives the firm significant influence over the company. The size of this position relative to the rest of the portfolio indicates that REZI is the primary driver of the firm's investment strategy for this period.
  • Agilon Health, Inc. (AGL): The second holding, valued at $103.00 million, represents 15.22% of the portfolio. The firm holds exactly 100.00 million shares. While significantly smaller than the REZI position, it remains a sizable investment in the healthcare sector, contributing to the portfolio's binary composition.

Quarter at a glance — Q1 2026

Position-change comparison pending.

No quarter-over-quarter changes available.

Top 10 holdings

By portfolio weight as of Q1 2026.

#HoldingValueSharesWeight
01
REZI
Resideo Technologies, Inc.
$505M15.0M94.1%02
AGL
Agilon Health, Inc.
$32M4.0M5.9%

Filing history

2026Q1Mar 31
$536M▼ 9.8%
2 positionsView →2025Q4Dec 31
$595M▼ 12.1%
2 positionsView →2025Q3Sep 30
$677M▲ 89.4%
2 positionsView →2025Q2Jun 30
$357M▼ 17.5%
2 positionsLocked2025Q1Mar 31
$433M▲ 124.8%
1 positionsLocked2024Q4Dec 31
$193M▼ 52.0%
3 positionsLocked2024Q3Sep 30
$402M▼ 39.3%
4 positionsLocked2024Q2Jun 30
$662M▲ 7.0%
4 positionsLocked2024Q1Mar 31
$619M▼ 83.4%
4 positionsLocked2023Q4Dec 31
$3.7B▼ 31.4%
5 positionsLocked2023Q3Sep 30
$5.4B▼ 20.5%
5 positionsLocked2023Q2Jun 30
$6.8B▼ 26.0%
7 positionsLocked
Showing 12 of 48